New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2021 Sep 27

PMID 34566724

Citations 7

Authors

Tehseen Noorani

Jonny Martell

Affiliations

Soon will be listed here.

Citing Articles

A Systematic Review of Study Design and Placebo Controls in Psychedelic Research.

Wen A, Singhal N, Jones B, Zeifman R, Mehta S, Shenasa M Psychedelic Med (New Rochelle). 2025; 2(1):15-24.

PMID: 40051762 PMC: 11658677. DOI: 10.1089/psymed.2023.0028.

Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience.

Wahba M, Hayes C, Kletter M, McAllister-Williams R BJPsych Open. 2024; 10(6):e229.

PMID: 39654264 PMC: 11698204. DOI: 10.1192/bjo.2024.768.

Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol.

Butler M, Bird C, Maggio C, Durden A, Modlin N, Campbell-Coker K Wellcome Open Res. 2024; 9:401.

PMID: 39372842 PMC: 11450546. DOI: 10.12688/wellcomeopenres.22543.1.

Editorial: Psychedelic humanities.

Noorani T, Davis O, Dymock A, Langlitz N, Schlag A, Dyck E Front Psychol. 2024; 15:1474064.

PMID: 39233887 PMC: 11371788. DOI: 10.3389/fpsyg.2024.1474064.

When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research.

Jacobs E, Murphy-Beiner A, Rouiller I, Nutt D, Spriggs M Neuroethics. 2023; 17(1):3.

PMID: 37942467 PMC: 10627912. DOI: 10.1007/s12152-023-09536-z.

References

OBrien P, Thomas C, Hodgkin D, Levit K, Mark T . The diminished pipeline for medications to treat mental health and substance use disorders. Psychiatr Serv. 2014; 65(12):1433-8. PMC: 4788407. DOI: 10.1176/appi.ps.201400044. View

Murphy R, Kettner H, Zeifman R, Giribaldi B, Kartner L, Martell J . Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. Front Pharmacol. 2022; 12:788155. PMC: 9009076. DOI: 10.3389/fphar.2021.788155. View

Miller F, Kaptchuk T . The power of context: reconceptualizing the placebo effect. J R Soc Med. 2008; 101(5):222-5. PMC: 2376272. DOI: 10.1258/jrsm.2008.070466. View

Rucker J, Young A . Psilocybin: From Serendipity to Credibility?. Front Psychiatry. 2021; 12:659044. PMC: 8096916. DOI: 10.3389/fpsyt.2021.659044. View

Carhart-Harris R, Wagner A, Agrawal M, Kettner H, Rosenbaum J, Gazzaley A . Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?. J Psychopharmacol. 2021; 36(1):6-11. PMC: 8801625. DOI: 10.1177/02698811211008567. View

Gallimore A, Strassman R . A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience. Front Pharmacol. 2016; 7:211. PMC: 4944667. DOI: 10.3389/fphar.2016.00211. View

Carhart-Harris R, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I . Psychedelics and the essential importance of context. J Psychopharmacol. 2018; 32(7):725-731. DOI: 10.1177/0269881118754710. View

Muthukumaraswamy S, Forsyth A, Lumley T . Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021; 14(9):1133-1152. DOI: 10.1080/17512433.2021.1933434. View

Davies J, Read J . A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?. Addict Behav. 2018; 97:111-121. DOI: 10.1016/j.addbeh.2018.08.027. View

10.

Hartogsohn I . Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. 2016; 30(12):1259-1267. DOI: 10.1177/0269881116677852. View

11.

Dauner D, Dauner K, Peterson A . FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients. Res Social Adm Pharm. 2019; 16(6):844-847. DOI: 10.1016/j.sapharm.2019.11.004. View

12.

Healy D, Mangin D . Clinical judgments, not algorithms, are key to patient safety-an essay by David Healy and Dee Mangin. BMJ. 2019; 367:l5777. DOI: 10.1136/bmj.l5777. View

13.

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R . Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021; 384(15):1402-1411. DOI: 10.1056/NEJMoa2032994. View

14.

Kaptchuk T, Shaw J, Kerr C, Conboy L, Kelley J, Csordas T . "Maybe I made up the whole thing": placebos and patients' experiences in a randomized controlled trial. Cult Med Psychiatry. 2009; 33(3):382-411. PMC: 2716443. DOI: 10.1007/s11013-009-9141-7. View

15.

Ly C, Greb A, Cameron L, Wong J, Barragan E, Wilson P . Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018; 23(11):3170-3182. PMC: 6082376. DOI: 10.1016/j.celrep.2018.05.022. View

16.

Marseille E, Kahn J, Yazar-Klosinski B, Doblin R . The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. PLoS One. 2020; 15(10):e0239997. PMC: 7556534. DOI: 10.1371/journal.pone.0239997. View

17.

Yaden D, Griffiths R . The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacol Transl Sci. 2021; 4(2):568-572. PMC: 8033615. DOI: 10.1021/acsptsci.0c00194. View

18.

Timmermann C, Watts R, Dupuis D . Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations. Transcult Psychiatry. 2022; 59(5):691-704. PMC: 9660279. DOI: 10.1177/13634615221082796. View

19.

Olson D . The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects. ACS Pharmacol Transl Sci. 2021; 4(2):563-567. PMC: 8033607. DOI: 10.1021/acsptsci.0c00192. View

20.

Carhart-Harris R, Kaelen M, Whalley M, Bolstridge M, Feilding A, Nutt D . LSD enhances suggestibility in healthy volunteers. Psychopharmacology (Berl). 2014; 232(4):785-94. DOI: 10.1007/s00213-014-3714-z. View